Phase III Tecentriq Study Shows Better Survival vs. Chemo Regardless of PD-L1 Status

Non-classical mutations present in 20-30% of all patients with EGFR-mutated NSCLC, analysis shows

Non-classical mutations are present in 20-30% of all patients with epidermal growth factor receptor-mutated non-small cell lung cancer, according to an analysis of real-world evidence presented by Black Diamond Therapeutics, Inc. at the American Association of Cancer Research annual meeting.

April 12, 2024

Vol.50 No.15

Clinical Roundup

Observational study demonstrates clinical validity and utility of OncoHost’s PROphet NSCLC test

A mutli-center observational study demonstrated the clinical validity and utility of the PROphet non-small cell lung cancer test, a plasma proteome machine learning-based decision-support tool designed to identify patient subsets benefiting from PD-1/PD-L1 inhibitor-based therapies.

March 29, 2024

Vol.50 No.13

Drugs & Targets

FDA approves Rybrevant for first-line treatment of EGFR-m NSCLC

FDA approved Rybrevant (amivantamab-vmjw) with carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor, or EGFR, exon 20 insertion mutations, as detected by an FDA-approved test.

March 08, 2024

Vol.50 No.10

Drugs & Targets

Elipses’s selective RET inhibitor EP0031/A400 granted Fast Track designation in NSCLC

FDA granted the next-generation selective RET inhibitor EP0031/A400 Fast Track designation for the potential treatment of RET-fusion positive non-small cell lung cancer.

March 08, 2024

Vol.50 No.10

Drugs & Targets

FDA approves Tagrisso + chemo for EGFR-mutated NSCLC

FDA approved Tagrisso (osimertinib) with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

February 23, 2024

Vol.50 No.08

Drugs & Targets

FDA accepts supplemental BLAs for two Opdivo regimens

FDA accepted the supplemental Biologics Application for neoadjuvant Opdivo (nivolumab) with chemotherapy followed by surgery and adjuvant Opdivo for the perioperative treatment of resectable stage 2A to 3B non-small cell lung cancer. FDA assigned a Prescription Drug User Fee Act goal date of Oct. 8.

February 09, 2024

Vol.50 No.06

Phase III Tecentriq Study Shows Better Survival vs. Chemo Regardless of PD-L1 Status

YOU MAY BE INTERESTED IN

Non-classical mutations present in 20-30% of all patients with EGFR-mutated NSCLC, analysis shows

Observational study demonstrates clinical validity and utility of OncoHost’s PROphet NSCLC test

FDA approves Rybrevant for first-line treatment of EGFR-m NSCLC

Elipses’s selective RET inhibitor EP0031/A400 granted Fast Track designation in NSCLC

FDA approves Tagrisso + chemo for EGFR-mutated NSCLC

FDA accepts supplemental BLAs for two Opdivo regimens

Renew today!

Subscriber content

Login